Issue #279
- Engineered Virus Targets HIV-Infected Cells: Interview with Garry Nolan, Ph.D.
- Efavirenz (SUSTIVA [tm]) Expanded Access Begins October 1
- Efavirenz (SUSTIVA [tm]), Formerly DMP-266) 48-Week Data Announced
- T-20: Entirely New Antiretroviral
- IDSA '97: Conference Without Activists
- IDSA '97: What It Did Right
- IDSA '97: Excellent Medical Summaries on Tape
source: AIDS Treatment News
